Subscribe or Manage Preferences

Melanoma Management

Zurich, Switzerland—In previously treated patients with advanced melanoma, single-agent nivolumab dem­onstrated long-term survival that compares favorably with current standard-of-care agents, according to F. Stephen Hodi, Jr, MD, Director, Melanoma Center, Dana-Farber/Brigham and Women’s Cancer Center, Boston. The CA209-003 phase 1 clinical trial also showed that responses occurring early were durable even after the discontinuation of therapy, said Dr Hodi at the 2014 Society for Melanoma Research International Congress.
Zurich, Switzerland—For regimens joining BRAF and MEK inhibition in BRAF-mutated melanoma, recent clinical trial data showing unequivocal overall survival (OS) improvements effectively “close the book” on defining clinical benefit, according to Keith T. Flaherty, MD, Director of Developmental Therapeutics, Massachusetts General Hospital Cancer Center, Boston. Increases in complete response (CR) rates, added Dr Flaherty at the 2014 Society for Melanoma Research International Congress, suggest that with longer-term follow-up, increases in durable responses will also be demonstrated.

Results 1 - 2 of 2
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology